University of Hong Kong study links osteoporosis drugs to lower Alzheimer's risk

A study conducted by the University of Hong Kong suggests that certain osteoporosis medications may be linked to a reduced risk of Alzheimer’s disease and related dementias. Researchers analyzed electronic medical records from over 120,000 individuals aged 60 and older between 2005 and 2020.

The findings specifically highlight nitrogen-containing bisphosphonates (NBPs), such as alendronate and zoledronate. According to the study, NBP users had a 16% lower risk of developing Alzheimer’s or other forms of dementia compared to untreated individuals. When compared to patients receiving other types of osteoporosis medications, the risk reduction for NBP users was even more pronounced at 24%.

The protective effect appeared most significant among women and patients who had previously suffered hip fractures. Researchers noted that because osteoporosis and dementia often affect similar aging populations and share risk factors, the specific properties of NBPs may offer a secondary neurological benefit beyond bone density maintenance.